Determining whether glucagon is understood to be a problem in diabetes which needs to be suppressed, or a solution to the global obesity epidemic, is likely to depend on which approach is successfully brought to market first, rather than the relative merits of the two approaches. This evidence concerns the gene GCG and obesity disorder.